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PURPOSE. To discuss guidelines and ethical considerations associated with the development
and prescription of treatments intended for myopia control (MC).
METHODS. Critical review of published papers and guidance documents was undertaken, with
a view to carefully considering the ethical standards associated with the investigation,
development, registration, marketing, prescription, and use of MC treatments.
RESULTS. The roles and responsibilities of regulatory bodies, manufacturers, academics, eye
care practitioners, and patients in the use of MC treatments are explored. Particular attention
is given to the ethical considerations for deciding whether to implement a MC strategy and
how to implement this within a clinical trial or practice setting. Finally, the responsibilities in
marketing, support, and education required to transfer required knowledge and skills to eye
care practitioners and academics are discussed.
CONCLUSIONS. Undertaking MC treatment in minors creates an ethical challenge for a wide
variety of stakeholders. Regulatory bodies, manufacturers, academics, and clinicians all share
an ethical responsibility to ensure that the products used for MC are safe and efficacious and
that patients understand the benefits and potential risks of such products. This International
Myopia Institute report highlights these ethical challenges and provides stakeholders with
recommendations and guidelines in the development, financial support, prescribing, and
advertising of such treatments.
Keywords: conflict of interest, ethical prescribing, informed consent, medical device, myopia
control
1. INTRODUCTION
Myopia currently affects approximately 30% of the globalpopulation and is predicted to affect 50% by 2050.1 Of
particular concern is the association of increasing levels of
myopia with a higher risk of potentially blinding ocular
pathologies, such as myopic macular degeneration (MMD),
glaucoma, cataract, and retinal detachment.2–9 Further details
are provided in the accompanying International Myopia
Institute (IMI) – Defining and Classifying Myopia Report.10
These complications mean that myopia is becoming one of the
major causes of vision impairment and blindness in the
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world,1,9,11 prompting interest in therapies to prevent myopia
onset and progression.
Recently, a number of interventional studies have been
conducted that attempt to prevent or retard the onset or slow
the progression of myopia. Treatment options include
increased time spent outdoors, pharmaceuticals, orthokeratol-
ogy (OK), soft multizone contact lenses, and progressive
addition and bifocal spectacle lenses.12–17 Further details can
be found in the accompanying IMI – Interventions for
Controlling Myopia Onset and Progression Report.18 These
approaches raise a number of ethical concerns and challenges
for the researchers and clinicians undertaking such treatments
in vulnerable populations. What potential conflicts of interest
(COI) require consideration? What are the regulatory consid-
erations for the prescribing clinician? What part does industry
play in the ethical conduct of myopia control (MC) studies?
What are the roles and responsibilities of the various
stakeholders that need consideration? How should the
information from MC studies be appropriately disseminated?
What are the relevant issues regarding education of prescribers
of MC treatments, and how should such products be marketed
to prescribers and patients?
In this paper, these questions are addressed by referring to
best clinical practice and adherence to the guidelines for
evidence-based practice.19–21
2. ETHICAL CONSIDERATIONS IN IMPLEMENTING AN
MC TREATMENT
From an ethical standpoint, deciding whether to implement an
MC strategy represents the classical medical risk versus benefit
ratio. A principal motivation for preventing myopia onset or
slowing myopia progression is based on the unverified premise
that limiting the extent of myopia progression reduces the risk
of the development of vision-threatening disease. Conclusive
evidence from appropriate clinical trials showing that prevent-
ing myopia onset and/or slowing myopia progression results in
the prevention of myopia-related ocular pathology is unlikely
to be available for decades. Nonetheless, if this assumption is
correct, then the benefits to individuals and society could be
substantial, given the clear relationship between myopia-
related ocular pathology and the amount of myopia.22 Clearly,
the risk-benefit analysis must take account of the outcomes
arising from nonintervention.
Another motivation in the use of MC therapy is the
avoidance of quality of life (QOL) problems arising from the
use of corrective devices, such as the inconvenience of
spectacle or contact lens wear, increasing reliance on
corrective devices, cultural stereotyping associated with
corrective eye devices, and the dysfunctionality and loss of
QOL that comes with use of corrective devices with high
prescriptions. Such influences may lead to introversion,
anxiety, low self-esteem, and less perceived attractive-
ness.23–26 QOL assessments show that spectacle and contact
lens-corrected myopes report increased concerns regarding
the likelihood of injuring themselves, difficulties coping with
normal demands of daily life, difficulties in fulfilling required
roles, and less confidence joining in everyday activities
compared to emmetropes.27 Adults with pathologic myopia
and associated visual impairment report experiencing signif-
icant social and emotional impacts and reduced life satisfac-
tion.28 The significant impact of myopia on visual function and
QOL must be considered when making clinical decisions
regarding treatments aimed to slow myopia progression in
children, and these considerations must play into the decision
concerning the appropriateness of intervening with a MC
strategy.
Other factors that must be accounted for in the decision to
undertake MC include the regulatory status of the treatment
being considered, availability of the treatment, access to skilled
eye care services, and pricing and convenience of the treatment,
which are all potential barriers to accessing treatment.
These considerations place a burden of responsibility on
the practitioner to be fully cognizant of the risks for the
patient of developing different levels of myopia, the
implications that progression to higher levels of myopia may
have, the likely benefits of treatment, the side-effects of
treatment, and other associated factors, so as to provide
appropriate advice and care.29 These issues are broadly
addressed in the accompanying IMI – Defining and Classifying
Myopia Report10 and the IMI – Interventions for Controlling
Myopia Onset and Progression Report.18
All parties have an ethical responsibility to promote the
patient’s welfare30 and to interact in an honest, open, and fair
manner in questions related to the quality of, and access to,
vision health care.31 Professions involved in delivery of eye
care have developed codes of ethics,31–35 and these are
particularly important to consider when making decisions
concerning the management of children with myopia.
Providing efficient and effective health care is becoming
more challenging, due to the increasing complexities of health
care systems globally.36,37 Modern health care systems are
often characterized by increasing demands for accountabili-
ty.30,38 In this complex environment, it is critical that health
care professionals (HCPs) remain focused on patient-centered
clinical practice. In this mode of practice, HCPs help patients
and their parents/guardians understand their clinical recom-
mendations and make informed choices from the potential
options for care. Ethical codes are general guiding principles
that help HCPs in their clinical decision-making and in
practicing in accordance with a set of expected stan-
dards.30,31,39,40 Clinical decisions must be targeted toward
ensuring the individual patient’s welfare. This includes referral
to another HCP if the HCP has more expertise in the area and
access to the best treatment for the patient in question.
As described in the American College of Physicians Ethics
Manual,41 HCPs have a ‘‘primary role as a patient’s trusted
advocate, and he or she has a responsibility to use all health-
related resources in a technically appropriate and efficient
manner.’’ The Hippocratic Oath (above all to do no harm)42
refers to doing what is in the best interest of the patient. This
requires balancing risks and benefits of any treatment under
consideration and making decisions that optimize benefits and
minimize risks for the patient. HCPs are expected to respect
the informed choices that a patient makes about their own
health. However, to make such informed decisions, patients (or
their guardians in certain cases) require appropriate education
based on the most up-to-date evidence-based health care
practice for the disease or treatment being discussed.
2.1 Conflicts of Interest
COI arise when commercial or other private interests are at
odds with the official and moral responsibilities of an individual
or entity in a position of trust.43–49 All HCPs function in
positions of trust and as a patient’s advocate. Other profes-
sionals involved in the discussions around MC, such as
researchers, are also placed in a position of trust and should
appropriately present results of research without overstating
their significance, so as not to unduly influence either a
clinician or patient in deciding to undertake MC treatment. The
Accreditation Council for Continuing Medical Education
defines commercial interest as ‘‘any entity producing, market-
ing, re-selling, or distributing health care goods or services
consumed by, or used on, patients’’.50
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COIs are common in medicine and almost impossible to
avoid in research conducted in either university or other
settings and that applies equally to MC research. Researchers
and clinicians often partner with companies to conduct MC
studies. However, there is a risk for these partnerships to
introduce bias in clinical practice, and HCPs should be aware
of the importance of evaluating any real or perceived COI
when recommending a management plan for MC. These
interactions between practitioners and producers and suppli-
ers of devices or drugs should meet the highest possible
standards of integrity and transparency. Relationships between
clinicians and patients should not be compromised by
commercial or other interests that could subvert the principle
that the interests of patients are of primary concern.
COIs are created when HCPs:
 accept company gifts of various kinds, including meals
and drug samples;
 act as promotional speakers or writers on behalf of
companies;
 have a financial interest in a medical product company
whose products they prescribe, use, or recommend.
All entities involved in MC practice or product development
must disclose any potential COI, including any research
funding sources. Various documents describe these COI that
must be openly declared by researchers, educators, and
company employees when discussing or presenting their
findings, regardless of the medium being used.44,45,47–49,51–57
2.2 Informed Consent
Unless treatments for MC are specifically approved for that
purpose, their use is considered off-label and, therefore,
adequate informed consent prior to their use should be
obtained to minimize potential misinterpretations and/or legal
claims.58–61 For detailed information on the informed consent
process, readers are referred to the US Office for Human
Research Protection62 and for more specific information on
informed consent for MC to the accompanying IMI – Clinical
Management Guidelines Report.63
Informed consent is not simply a signature on an informed
consent form but, rather, it is a process of communication
between the HCP and the patient. Each patient must be fully
informed to balance the risks of no treatment against the risks
of treatment. Eye care professionals (ECPs) are encouraged to
rigorously apply informed consent processes whenever pre-
scribing or recommending off-label treatments for MC.
Providing full disclosure to patients and their families and
encouraging them to participate in the decision-making
process is vital to the value we place on patient autonomy.
The majority of MC treatments are currently off-label in
most countries. Some organizations, such as the Food and Drug
Administration (FDA), do not restrict HCP from discussing off-
label treatment uses or distributing written materials concern-
ing them. Given that patients and their families generally
assume that a treatment prescribed by their clinician has been
proven safe and effective and is supported by scientific
evidence, we recommend all practitioners to follow the
doctrine of informed consent, regardless of whether the
treatment is prescribed on-label or off-label. Therefore,
disclosing the nature, risks, benefits, and alternatives for each
MC treatment is vitally important.
Most patients seeking MC treatments are children under the
age of legal emancipation, and they are, therefore, accompa-
nied by their parents or legal guardians. This population is
categorized as a vulnerable population for clinical research and
clinical care.64,65 It is recommended that practitioners provide
documentation to vulnerable populations (specifically minors
in the case of MC) in the form of a written ‘‘assent’’ document.
The assent document should at a minimum include the
following (see Appendix for an example):66–70
 Text using developmentally appropriate language aimed
to help the patient become aware of:
* the nature of the condition (i.e., myopia);
* what to expect with each of the recommended MC
treatment(s).
 An assessment of the patients’ understanding and the
factors influencing how they are responding, including
whether there is inappropriate pressure to accept the MC
therapy.
 Soliciting an expression of the patient’s willingness to
accept the proposed MC treatment. If the patient will
have to receive medical care despite their objection, the
patient should be clearly told that fact.
As children develop, they should gradually become the
primary guardians of personal health and the primary partners
in medical decision-making, assuming responsibility from their
parents. HCPs should give serious consideration to each
patient’s developing capacities for participating in the deci-
sion-making process, including rationality and autonomy. The
assent process empowers children to the extent of their
capacity.71 In addition, HCPs must be aware of their country,
region, or state’s regulatory laws on legal age of adulthood and
whether minors have authority to make health care decisions,
and whether they have legal obligation to obtain parental and/
or minor’s consent. Just as is the case with informed consent,
the emphasis on obtaining assent should be on the interactive
process, in which information and values are shared and joint
decisions are made.
Decision-making involving the health care of older children
and adolescents should include, to the greatest extent feasible,
the assent of the patient as well as the participation of the
parents/guardians and the HCP. Current literature suggests that
adolescents, especially those age 14 and older, typically have
well-developed decisional skills and are capable of making
informed health care decisions.72
2.3 Cost Considerations
Treatment for MC includes prescription of specially designed
spectacles or contact lenses, or the use of pharmaceutic agents
such as atropine, in addition to recommendations on various
aspects of visual habits. The cost for these treatments may be
higher than the cost of typical eye examinations and correction
of myopia, due to the specialized equipment and extra time
taken for their appropriate fitting and education on use.
In most countries (e.g., United States, United Kingdom, and
Australia), a consultation fee for a comprehensive eye
examination is required. In other countries (e.g., China, South
Korea, and Cambodia), this consultation fee may be incorpo-
rated into the cost of the optical correction treatment. Given
the wide variability in vision and eye health care costs, it is not
possible to standardize a cost structure for MC treatment. In
China, for example, patients visiting optical shops for
refraction and vision correction would normally not pay a
consultation fee and would only pay for the cost of the optical
correction. However, those patients attending an eye clinic,
hospital or optometric center for MC treatment are charged a
fee for an annual ‘‘package treatment’’. These packages
typically include the original eye examination and follow-up
visits as well as the treatment costs. Costs are often driven by
the channels of service and public awareness.
One important aspect of MC to be considered when
evaluating the cost of MC treatments is the availability of a
number of treatments that may be beneficial for an individual
IMI – Industry Guidelines for Myopia Control Studies IOVS j Special Issue j Vol. 60 j No. 3 j M163
Downloaded from iovs.arvojournals.org on 08/12/2019
patient and the importance of not focusing on one specific
product or treatment that the provider may be familiar with.
Cost should not be considered in isolation but rather as the
cost-to-benefit ratio for each individual patient. Benefits will be
measured in terms of slowing the progression of myopia
compared to what would be expected for that specific patient
(considering the age of the patient, age of onset, number of
parents with myopia, recent progression, amount of myopia,
and visual environmental risks). Risks should include an
evaluation of the risk of developing myopia progression and
associated risk of developing pathology if left untreated. For
example, an expensive treatment that has only shown benefit
in a small subpopulation of patients, or if the effect found is not
clinically significant, should not be considered cost effective.
Similarly, if the patient’s myopia has already ceased to progress,
MC treatments should not be recommended if the treatment
cost is greater than that associated with standard vision
correction.
3. STAKEHOLDERS: ROLES AND RESPONSIBILITIES
ECPs have a responsibility to care for their patients by
recommending MC treatments by using evidence-based prac-
tice and their informed clinical judgement. Evidence-based
practice is a guiding principal used in making determinations
about the most effective treatment to use for the diagnosed
condition. It involves using both the current best evidence
available (e.g., randomized masked clinical trials and systematic
reviews) and replication of the findings by independent
researchers, in addition to individual clinical experience.73,74
With a condition as multifactorial and individual as myopia, this
means using published evidence along with clinical judgement
to determine the best course of action for the young myopic
patient. There is clearly a pressing need for the development
and availability of clinically proven, effective methods to slow
the progression of myopia. However, to date, few methods are
available and those that are available are often used ‘‘off-label.’’
The rising incidence of myopia is driving off-label/unlicensed
use of MC treatments in the absence or limited availability of
licensed options. Whereas regulatory bodies have the essential
role to ensure that medical products meet the highest
standards of safety, efficacy, and quality before they become
commercially available, the lack of approved treatment options
for MC represents an unmet medical need and a challenge for
all stakeholders concerned.
The following section provides information on a variety of
aspects related to the role and responsibilities of various
stakeholders in the prescription of treatments for MC in the
pediatric population.
3.1 Regulatory Bodies
3.1.1 Regulatory Process for Marketing Medical
Products. Marketing a medicinal product requires a marketing
authorization (‘‘product license’’) for specified indications
under specified conditions (e.g., target population, indication,
and specific use), regulated by the country’s medicines and
health care products regulatory agency.75,76 The marketing
authorization for the product includes the agreed terms of use
(the ‘‘label’’), described in the summary of product character-
istics. This process is used to ensure that medical products
meet the highest standards of safety, efficacy, and quality before
issued a marketing authorization.
Prescribing a licensed product outside of the approved
scope of use is called ‘‘off-label’’ prescribing, whereas
prescribing a product that does not hold a marketing
authorization is termed ‘‘unlicensed’’ prescribing. HCPs
sometimes practice off-label/unlicensed prescribing to address
a deficit in effective products that are approved. Manufacturers
are prohibited from marketing or promoting off-label/unli-
censed uses of products to induce commercial sales (‘‘mis-
branding’’). Regulatory bodies, however, do not normally
regulate the way medicinal products are ultimately used in
practice. The prescribing of a medicinal product, regardless of
whether on-label, off-label, or unlicensed, is a decision taken
within the relationship between the patient and the HCP.
a) On-Label Versus Off-Label Use. The term ‘‘off-label use’’
is widely used. The most common definition is the prescription
of a medication or device that is available and marketed but for
a different indication than it was approved for by the
appropriate regulatory body. Off-label uses include giving an
approved drug (or device) for a disease or indication other than
the disease for which it is approved; at a different dose,
frequency, or route of administration than specified in the
label; or to treat a child when the product is approved to treat
adults.77 All of these instances could apply to the prescribing of
MC products that are approved for other uses but not
specifically approved for MC.
The FDA in the United States recommends that good
medical practice and the best interests of the patient require
that physicians use legally available drugs, biologics, and
devices according to their best knowledge and medical
judgment. If physicians use a product for an indication not in
the approved labeling, they have the responsibility to be well-
informed about the product, to base its use on firm scientific
rationale and on sound medical evidence and to maintain
records on the product’s use and effects. Use of a marketed
product in this manner when the intent is in the practice of
medicine does not require the submission of an Investigational
New Drug Application or review by an institutional review
board (IRB). However, the institution at which the product will
be used may, under its own authority, require IRB review or
other institutional oversight.
It is important to note that the FDA does not regulate
medical practice in the treatment of an individual patient, but it
plays other important roles, such as precluding pharmaceutic
companies from marketing drugs to physicians, other HCPs, or
patients for off-label use. It is, therefore, recommended that
ECPs prescribe devices and medications only for indications
they and their peers believe to be in the best interest of the
patient. This will include MC treatments. In addition, it is the
obligation of HCPs to educate themselves and their patients on
the risks and benefits of each potential treatment to provide
the best possible care for their patients. In the context of ECPs
instigating MC therapies, the same requirements and respon-
sibilities would apply.
Off-label and unlicensed prescribing use can occur due to a
number of factors, including extended timelines in product
development and/or the process of regulatory approval for
authorized use, particularly in patient populations (e.g.,
pediatrics) or disorders (e.g., psychiatric) that are inherently
difficult to study and, thus, are often excluded from clinical
studies. If a product is discovered to be effective in treating a
second indication, obtaining approval to treat the new
indication often involves a second regulatory pathway that
can be both lengthy and costly. Furthermore, even if the new
indication eventually becomes approved, revenues for the new
indication may not offset the expense and effort required to
obtain approval.78 In some countries, legislation may allow
extended market protection time for a new indication that
exhibits additional significant clinical benefits over existing
therapies. This is provided that it is registered in the
subsequent years after the initial marketing authorization has
been granted.79,80 These regulatory hurdles, together with
commercial risks such as low return on investment, particu-
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larly with off-patent products, and challenges related to pricing
and reimbursement, play a role in preventing wider availability
of on-label options in specific patient groups. Additionally, the
ongoing elevation of regulatory compliance obligations, which
inevitably culminates in longer development and approval lead
times, are likely to exacerbate the lack of availability of on-label
products.
b) Frequency of Off-Label Use. The frequency of off-label
use is generally high, covers a broad range of therapeutic areas,
and is common practice for many prescribers all over the
world, in particular in the areas of pediatrics, oncology,
neurology, infection, and geriatrics.75 In China, one survey
revealed that off-label drug use accounts for up to 22% of all
medicines prescribed, despite being prohibited.81 It has been
reported that off-label prescriptions are significant in the
United States, being greater than 50% in some groups of
patients.81 Analysis of physician-prescribing habits in the
United States revealed that overall, 21% of prescriptions were
used off-label.82 For certain medications, off-label prescribing
was as high as 83%. In certain cases, or with certain classes of
patients, more than 50% of them may receive at least one off-
label drug. A previous study found that 79% of children
discharged from pediatric hospitals were taking at least one off-
label medication.83 In a pediatric emergency department, the
rate of off-label drug prescribing was estimated to be 26%.84 In
Europe, up to 90% of treatment for infants in hospital intensive
care units is understood to be off-label.81 A study by the
European Union (EU) found a rate of off-label prescribing
ranging from 13% to 69% of the prescriptions investigated in 32
studies, which took place in various pediatric populations
within a hospital setting, covering data from 16 EU member
states.85 In 40 studies in the outpatient setting, covering data
from 12 EU member states, there was a range of 2% to 100% of
off-label prescribing.85 A study performed in a mother-child
tertiary care hospital in Canada found that 8% and 38% of
prescriptions issued on a randomly selected day were
unlicensed and off-label, respectively.86
c) Advantages and Disadvantages. Advantages and
disadvantages have been described with regard to off-label/
unlicensed use of medical products.85 A major advantage might
be giving better access to relevant and innovative treatments
and the fulfillment of the medical needs of patients, especially
in cases where there are limited or no options available. It may
also provide a level of health care that is not ordinarily available
to the patient, due to cost- or time-related issues and, as such,
may contribute to a positive medical outcome. Additionally, off-
label/unlicensed use has significant economic implications in
that it contributes to the sustainability of the health care
system. In contrast, when economic justification is the
prevailing rationale for off-label/unlicensed prescribing, fric-
tion between national authorities and industry might occur.
Also, potential liability arising from unsuccessful off-label/
unlicensed use is a concern for prescribing stakeholders.
3.1.2 Current Regulatory Status of MC Treatments. The
majority of medical and surgical devices used in children do
not have approval or clearance from regulatory bodies for use
in pediatric populations.87 For example, morphine has never
been approved by the FDA for pain treatment in children, but it
is widely used for this indication in hospitalized pediatric
patients.83 Similarly, many inhaled bronchodilators, antimicro-
bials, anticonvulsants, and proton pump inhibitors are used in
pediatric patients, without FDA approval for use in this
population.88 There are many such examples of off-label use
in ophthalmology. For example, antibiotic eyedrops, which are
approved for specific forms of ocular infections, are used off-
label for prophylaxis in ophthalmic surgery. In fact, antibiotic
eyedrops are considered today the standard of care globally in
preventing ocular infections in the perioperative period.
However, they are rarely approved for this use.
The clinical need for devices to diagnose and treat diseases
or conditions occurring in children has led to the widespread
use in pediatric medicine and surgery of approved devices that
do not hold a marketing authorization to provide medical care
to children but that are used ‘‘off-label.’’75 The latter has led to
different professional associations reporting policy statements
supporting off-label and unlicensed use, particularly whenever
effective on-label options are not available. For example, the
American Academy of Pediatrics has very recently provided a
policy statement reporting:
‘‘. . .off-label use is legal, is not regulated by regulatory
bodies, and is considered by regulatory bodies to be the
practice of medicine. Without such use, children may be
left with no therapeutic options and, in fact, the off-label
use of many devices has become the most common and
appropriate practice in pediatrics, often supported by
published data, professional guidelines, and expert opin-
ions. The American Academy of Pediatrics recognizes that
the use of off-label devices is not ideal, but often is
necessary in children. For children, off-label approved
devices are often the safest and most effective therapy
available.’’87
Similarly, the American Society of Health-System Pharma-
cists recommends that off-label drug information undergo an
evaluation process similar to that applied to materials for
indicated uses. More specifically, the American Society of
Health-System Pharmacists recommends before considering
off-label use, supporting safety and efficacy evidence must be
carefully evaluated and a risk-benefit determination made,
especially when FDA-approved alternatives are available for the
intended off-label use.89 The American Medical Association has
reported:
‘‘. . .when the prescription of a drug or use of a device
represents safe and effective therapy, third-party payers
should consider the intervention as reasonable and
necessary medical care, irrespective of labeling, and should
fulfill their obligation to their beneficiaries by covering such
therapy.’’90
Contact lenses, which typically have a marketing authori-
zation for lens wear in adults only, are frequently fitted ‘‘off-
label’’ to minors. The available documentation at the time of
approval is usually sparser in children when compared with
adults, and long-term data collection may be needed to support
its safety profile; this is particularly relevant to detect any long-
term or delayed complications in the child’s developing eye.
Furthermore, concerns have been raised with regard to the
possibility that children might be qualitatively and quantita-
tively at a higher risk than adults when exposed to the use of
medical products approved for use in adults only.91 Although
the latter may be theoretically possible with the off-label use of
contact lenses in children, recent studies have shown that
children do not have a higher risk than adults of suffering from
contact lens-related complications with either OK92,93 or soft
contact lens wear.94 Based on their relative safety profile92–95
and significant levels of MC efficacy reported in the scientific
literature,13,15,17,96 OK and multifocal soft contact lenses
appear to represent a viable MC treatment option for children.
With regard to the use of spectacle lenses in children, there
are no safety-related concerns. However, the use of progressive
addition and bifocal spectacles typically produces more modest
MC treatment effects than OK and multifocal soft contact
lenses (see the accompanying IMI – Interventions for
Controlling Myopia Onset and Progression Report).18 The
IMI – Industry Guidelines for Myopia Control Studies IOVS j Special Issue j Vol. 60 j No. 3 j M165
Downloaded from iovs.arvojournals.org on 08/12/2019
effects mainly occur in the first year of treatment; however, the
treatment effect appears to be more significant in children
with faster myopia progression, larger lags of accommodation,
near esophoria, shorter reading distances, and/or lower
baseline myopia.97–106 There are controversies with regard to
the use of progressive addition and bifocal spectacles for MC,
as some studies have found larger treatment effects occurring
over a period of at least two years of lens wear,12,107 whereas
others carried out with progressive addition lenses designed to
reduce peripheral hyperopic defocus have found minimal
impact on reducing myopia progression.108,109 Despite this,
spectacle designs for MC are a necessary consideration,
particularly in cases where other treatment options are not
feasible (e.g., very young children, those unable to wear
contact lenses due to access or cost, situations associated with
poor hygiene conditions, or remote locations far from
specialized eye care). Furthermore, a reserve pair of spectacles
to the most recent prescription is always recommended for
contact lens wearers. Therefore, the continued investigation
and approval of optical designs for slowing the progression of
myopia in children with spectacles lenses is warranted.
Well-designed studies using topical 0.5% and 1% atropine
have demonstrated significant reductions in the progression of
myopia.16,110–112 However, its use has been associated with
side and rebound effects that many clinicians consider
unacceptable for long-term therapy.113–116 Low-dose topical
atropine has also shown promising effects in slowing myopia
progression, and its use is associated with minimal adverse and
rebound effects,113–116 thus representing a potentially viable
therapeutic option for MC in children.16,112,117 Atropine is
neither commercially available in adequate dosage nor
approved for MC in children in the majority of countries
today. This is mainly because atropine eyedrops, which have
been used for many years, are not easily patentable for MC,
resulting in industry reticence in pursuing formal drug
approval with regulatory bodies, given the considerable
financial outlay for long-term clinical trials in large groups of
pediatric patients. However, at the time of writing this
manuscript, several commercial preparations of low-dose
atropine have been submitted for regulatory approval.
3.1.3 Efforts to Increase Approved Medical Products
in Children. In view of the limited treatment options
currently approved for MC in children, efforts and initiatives
previously proposed in other medical disciplines as well as
other possibilities to increase approved medical products in
children at the governmental, regulatory, health care, and
professional level are worthy of discussion, with a particular
focus on how these initiatives could be potentially applied to
speed up the approval of drugs and devices for MC in children.
a) Governmental. Due to a historic lack of scientific
evidence available to substantiate submissions for devices that
are indicated for use in the diagnosis or treatment of pediatric
patients, several initiatives in the United States and Europe and
at the World Health Organization have been introduced over
the last two decades to promote the development of on-label
products for children.118
In 1997, the FDA adopted the Modernization Act,119
followed in 2002 by the Best Pharmaceuticals for Children
Act,120 which provides an incentive for drug companies,
including exclusive marketing and patent extension, to
conduct FDA-requested pediatric studies.121 In 2003, the FDA
also created the Pediatric Research Equity Act, which requires
drug companies to study their products in children under
certain circumstances.122 In 2004, the FDA published a
guidance document entitled ‘‘Premarket Assessment of Pediat-
ric Medical Devices - Guidance for Industry and Food and Drug
Administration Staff’’ to clarify the types of information needed
to provide reasonable assurance of safety and effectiveness of
medical devices intended for use in pediatric patients and to
promote the development of these devices, which was
updated in 2014.123 The latter version of the document
indicates that data can be extrapolated to support effectiveness
and, on a limited basis, safety for premarket approval (PMA)
applications when consistent with scientific principles. More
specifically, it provides criteria to be considered when
evaluating the relevance and value of using nonspecific
comparative data (such as that from adults or from a different
pediatric subpopulation) and to determine if it can be
extrapolated to support use in pediatric populations. It also
addresses the premise of leveraging relevant available clinical
data that may lead to more devices being granted marketing
authorization for pediatric indications. This could result in an
increase in the availability of medical devices, with appropriate
labeling, to support safe and effective use in pediatric patients.
Similarly, in 2006 the EU established incentives to conduct
research and development of innovative products and to
encourage the marketing authorization of medicinal products
which fulfill a medical need.124 In theory, such initiatives
should incentivize the development of more on-label options
and, in turn, reduce off-label and unlicensed use for the
pediatric population within EU member states. In 1999, the
Japanese Ministry of Health, Labour and Welfare introduced a
program whereby, under certain conditions, it would approve
a new supplement for a drug indication without clinical trials.
This approval scheme involves an application based on
evaluation of literature-based evidence. However, the type of
indications and the kind of evidence used in practical
applications remain to be clarified.125
Despite the above government efforts, there has been no
significant increase in the number of drugs that have
supporting pediatric data at the time of their approval.126 In
fact, pediatric drug approvals and labeling revisions continue
to lag behind their adult counterparts.127 Nevertheless,
companies pursuing marketing authorizations for MC in
children should take the above initiatives into account and
governments are encouraged to follow the growing movement
toward harmonized regulatory systems. Proliferation of differ-
ent national regulations increases costs, hinders access to
health care technologies, and can even unwittingly jeopardize
the safety and health of the patient.128 Certainly, having to
meet diverse regulatory requirements in different markets that
are both lengthy and costly is going to prevent companies from
pursuing marketing authorization for MC for products that
might be already available in the market and could be used off-
label.
b) Regulatory. Exploring possibilities of including alternate
evidence to industry-funded randomized controlled trials for
the marketing authorization of off-label indications and the
conditions under which this would be possible have been
proposed previously.85 Evidence from peer-review clinical
trials, monitoring of patient cohorts, data from routine patient
registries, and data from reported adverse events are all
examples of sources of evidence to support safety and efficacy.
This option could be considered for MC, where a number of
methodologies and their attendant devices have accumulated
evidence for efficacy, from case reports, retrospective and
prospective clinical studies, and meta-analyses, supporting
their role as effective and relatively safe treatment options for
MC.12,13,15–17,96,129 Furthermore, some optical devices have
been available on the market for a number of years for use in a
different patient population (i.e., adults) and can be referenced
as supporting evidence for the safety and efficacy of such
devices for MC in children.
Creating and/or enhancing incentives for companies to
register new indications for existing products should also be
considered and could include tax breaks, exclusive marketing
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rights, increased time of market protection, and reduced
application fees.75,85 These proposals, if successfully applied,
are likely to incentivize optical companies in pursuing
marketing authorizations for MC in children. Legal frameworks
to issue temporary recommendations for use and permission to
prescribe off-label could also be taken into consideration. Such
a scheme of temporary recommendation is currently in use in
France and Hungary, where prescribers or their organizations
have to ask permission to prescribe a product off-label.85
Providing guidance on off-label use in the form of treatment
guidelines is another possible option to consider. A position
paper by the European Society for Medical Oncology has
argued for regulatory bodies to facilitate the production of
compendia of anticancer drugs, enlisting those off-label uses
judged to be legitimate.130 According to this position paper:
‘‘. . .this would not solve the whole problem at once, but it
would at least clarify the situation and improve the
physician’s position, particularly regarding the question of
medical liability, when confronted with the described
paradoxes of off-label drug use.’’
The American Academy of Pediatrics has provided guide-
lines on a number of topics, including the off-label use of
medical devices.87,131 Of greater relevance is that the scientific
bureau of the World Society of Pediatric Ophthalmology and
Strabismus has recently reported guidelines on current
approaches for MC treatment.132 Additionally, a recent report
by the American Academy of Ophthalmology concludes there
is solid scientific evidence that supports the use of low-dose
atropine to prevent myopic progression.112
c) Health Care. A policy option that could be considered is
to develop a consensus list of accepted off-label/unlicensed
uses of medical products for MC in children. The list could be
based on solid scientific evidence or there could be a process,
including, for example, evaluation by a subject-matter expert
group, by which to approve such applications for promoting
safer off-label and unlicensed use of medical products for MC in
children.133 This kind of process could be developed for ECPs
to apply for permission to prescribe off-label/unlicensed
products with the appropriate competent authority. The
application could be evaluated with respect to its efficacy
and safety, and an appropriate decision made. This would offer
a balance between the benefits and risks of off-label/unlicensed
use for patients. Additionally, implementing reimbursement
measures to influence off-label/unlicensed use may also need
to be considered. For example, France and Italy explicitly allow
for reimbursement of off-label use when no alternative on-label
options exist.85 Such possibilities might help ECPs handle the
ethical and legal paradoxes associated with the prescription of
off-label and unlicensed treatment options for MC. At the same
time, this may lead to a safer and more consistent prescription
path for patients.
d) Professional. Safeguarding the safety, efficacy, and
quality of MC treatments is, to a significant degree, related to
the expertise of ECPs in the field. From such a perspective, the
development of certified programs to ensure requisite compe-
tency standards of clinical practice in prescribing such
treatments might be desirable. Although these programs may
be developed in different forms and by different organizations,
development by professional bodies at a national level might
provide a better means of achieving higher and more
consistent standards of practice. As an example of such a
scheme, the United Kingdom College of Optometrists offers
higher qualifications in a number of specialized areas (i.e.,
contact lens practice, glaucoma, independent prescribing, low
vision, medical retina, and pediatric eye care) to enable
optometrists to offer enhanced services. Similarly, US state
boards certify doctors of optometry on a variety of expanded
therapeutic procedures (e.g. expanded therapeutic laser
practice). In The Netherlands, off-label prescription is only
allowed if the relevant professional body has developed
protocols or professional standards with regard to that specific
off-label use. The United Kingdom General Medical Council
provides guidance on good practice in prescribing and
managing medicines and devices.134 These latter options might
be particularly relevant considering it would be difficult for
ECPs to independently maintain a level of relevant competency
in the rapidly changing field of MC.
Nevertheless, safeguarding public health should always
remain the primary goal over and above any economic
considerations. As such, special care must be taken when
designing or adopting any of the above suggestions to increase
approved treatment options for MC in children, particularly
bearing in mind that off-label and unlicensed promotion may
challenge the integrity of the regulatory system by undermin-
ing the authority of regulators and discouraging companies
from conducting trials for new medicines and devices as well
as new indications.
3.2 Manufacturers
Manufacturers have a large part to play in the ethical decisions
around the ECP prescribing of MC treatments.
3.2.1 Requirements for Advertising MC Treatments. To
date, there are only two treatments that have been granted
marketing authorization in certain markets for on-label
prescribing in children for the purpose of MC (see the
accompanying IMI – Interventions for Controlling Myopia
Onset and Progression Report).18 Manufacturers cannot
directly market other products for MC. In the United States,
the FDA, through its division of drug, advertising, marketing,
and communications, regulates off-label drug promotion.
However, in practice, its capacity in such regulation is limited.
Several reasons have been proposed in favor and against
promoting off-label use of drugs and devices (Table 1).135
Although the FDA prohibits the promotion of off-label use of
drugs and devices, some sources of off-label use information
are permitted (Table 2).135
The FDA demands information regarding off-label use to be
accurate, the relationship between the distribution of informa-
tion and the sponsoring manufacturer be disclosed, and the
published material not be edited or presented in an abridged
form. Furthermore, such promotional materials must be
submitted to the FDA at the time of dissemination to the
public.136 As a result of the increase in direct-to-consumer
marketing by pharmaceutic manufacturers, the FDA introduced
the Truthful Prescription Drug Advertising and Promotion (Bad
Ad) Program in 2010. This program provides a mechanism by
which the HCPs and patients can report illicit off-label
promotion to the FDA. Despite regulations that prevent
pharmaceutic and marketing companies from promoting off-
label drug uses, off-label marketing by pharmaceutic companies
has been reported to be one of the most common causes of
Medicaid fraudulent claim investigations in the United
States.84,137 Several pharmaceutic manufacturers have faced
large settlements for illegal marketing of off-label uses.138–140
In Europe, EU law prohibits companies from marketing off-
label/unlicensed drugs and devices. In some European
countries, industry self-regulatory bodies monitor compliance
with marketing rules. For example, the United Kingdom self-
regulatory system for exposing marketing violations relies
mostly on complaints from company outsiders, which may
explain why most off-label promotion rulings relate to plainly
visible promotional activities, such as advertising. This
contrasts with the United States, where investigations by
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the Department of Justice and whistleblower testimonies
have alleged complex off-label marketing campaigns that
remain concealed to company outsiders.141 European author-
ities might need to consider introducing increased incentives
and protections for whistleblowers combined with United
States-style governmental investigations and meaningful
sanctions.
Prescribing off-label and unlicensed MC treatments is being
practiced worldwide,142 and it is likely to grow with the
increasing levels of myopia worldwide.1 As the interest in
prescribing treatments for MC increases, having access to
evidence supporting safety and efficacy, particularly for off-
label/unlicensed treatments, is essential. From this perspective,
industry should be encouraged to compile information from
the literature and other reliable sources that are evidence-based
to share with ECPs so they can make balanced, informed
clinical decisions that are a public health benefit.143 This is
particularly important considering that medications are often
prescribed for off-label use with absent or limited clinical
evidence.82
3.2.2 Efficacy Claims. MC efficacy relates to the reduction
in axial elongation and/or increase in manifest myopia of the
eye by the test device compared with a reference control
device. Further information on this topic is provided in the
accompanying IMI – Interventions for Controlling Myopia
Onset and Progression Report18 and the IMI – Clinical Myopia
Control Trials and Instrumentation Report.144
There are two issues in assessing efficacy in this respect that
warrant discussion. Firstly, ocular growth and refraction cannot
be assessed simultaneously with the test and control devices in
the same eye. Randomized, controlled clinical trials are the
gold standard to minimize bias, but case-control trials are also a
commonly accepted means of assessing efficacy. In both
TABLE 1. Reasons Proposed in Favor and Against Promoting Off-Label Use of Drugs and Devices in the United States. Text Quoted and Adapted
From Ventola135
Reasons in Favor Reasons Against
Can increase access to suitable off-label drugs for patients with rare
and other diseases.
Can increase abuse and over-promotion of off-label when appropriate
risk-to-benefit ratio has not been well established.
Off-label uses are important and even represent the recognized
standard of care for some conditions.
Peer-review alone does not ensure that off-label information will be
of a high quality.
Public health might be advanced if health care professionals were to
receive journal articles and references that are truthful and not
misleading about unapproved uses.
Strategic decisions made by industry sponsors might solely seek
publication of positive trial results.
More data and better transparency to be readily available to
physicians, enabling them to make better treatment decisions.
Misleading portrayal and interpretations of data in low quality
studies.
Relaxing restrictions enables clinicians to become more
knowledgeable about treatment alternatives as it is extremely
difficult for them to independently keep up-to-date in reading all of
the medical journals and compendia available.
Patients may still have to pay high treatment costs directly out of
pocket for off-label products that their health professional has
been encouraged to use.
The distribution of high-quality, focused information on off-label uses
by manufacturers could therefore be seen as an important service if
not abused.
Ghostwriting of journal articles sponsored by companies.
Supports innovation in clinical practice, which is particularly important
when approved treatments have failed to deliver adequate care.
Limited ability of regulatory and medical journals to detect low
quality studies.
Can keep medical practitioners informed about the treatment options
available for patients afflicted with rare diseases where manufacturers
have little economic incentive to conduct expensive clinical trials for
drug or device to be used to treat small patient populations.
Peer-review is insufficient protection against corporate influence
over the content of publications.
Because the regulatory approval process is complex, costly, and time-
consuming, the distribution of off-label drug information provides
physicians and patients with early notification about novel treatments.
Clinicians might rely solely on industry-distributed journal articles.
Gives patients opportunity to benefit from innovations that are
continuously developed in clinical practice (e.g., aspirin was widely
prescribed to reduce the risk of heart attacks long before the FDA
approved it for this purpose).
Editors and manuscript reviewers might not be familiar with critical
details of clinical study design and conduct and could unwittingly
publish poor quality or biased data.
Valuable in updating treatment decisions because knowledge on off-
label prescribing can play a key role in keeping up with rapidly
changing prescribing practices.
Suppression of data on safety risks.
Reduction in resources and cost-saving for regulatory bodies.
TABLE 2. Sources of Off-Label Use Information Permitted by the FDA.
Text Quoted and Adapted From Ventola135
Sources of Off-Label Use Information Permitted by the FDA
Compendia and drug/device information reference handbooks that
are published by organizations or companies that are independent
from manufacturers.
The presentation of scientific information in continuing medical
education programs.
The dissemination of journal articles that discuss not yet approved
product usages if FDA regulations are met.
Medical and graduate education in which off-label/unlicensed uses
are discussed, although disclosures of significant financial
relationships between program faculty and industry is requested.
Medical liaisons – companies are allowed to respond to unsolicited
questions from HCP about off-label/unlicensed uses.
Sales representatives are allowed to provide copies of peer-reviewed
journal articles to HCP, but are not permitted to use them to
promote company products.
Off-label data may be freely posted in web sites that are not agents
of the manufacturer.
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scenarios, changes in refractive error and/or axial length are
compared between test and control devices to evaluate MC
efficacy. The second issue is related to the metric used to assess
efficacy. The measurement of refractive error, which should be
ideally undertaken under cycloplegia and using automated
refraction to minimize potential patient- and examiner-subjec-
tive bias, is the clinical standard used to assess myopia
progression. However, some optical devices can impact the
reliability and repeatability of refraction measurements. Optical
biometry using low-coherence interferometry technology
allows objective measurement of axial length with a resolution
below 10 lm. Such technology145 is considered the gold
standard to quantify the axial elongation of the eye in myopia
progression146 and MC studies.147,148
Changes in axial elongation for contact lens MC studies
correlate reasonably well with changes in myopia progres-
sion.149,150 Results from 9 MC studies published over the last 8
years with OK 147,148,151–154 and other contact lens types154–156
have reported mean increases in axial length in the experi-
mental and control groups over a 2-year period of 0.33 mm and
0.55 mm, respectively, accounting for an average MC effect of
41%. However, it should be noted that calculation of MC
efficacy based on refractive error measurements tends to be
slightly higher than that calculated based on axial length,17,157
and thus, these two ways of calculating efficacy are not
interchangeable. It has been reported that emmetropic eyes
can remain emmetropic in spite of increases in axial length of
the order of 0.1 mm/year, whereas eyes that eventually develop
myopia have been reported to grow at a rate of 0.2 to 0.3 mm/
year over a period of 10 years before and after myopia onset.158
Studies on the use of atropine have shown a poorer
correlation between axial elongation and refractive error, with
refractive error reductions in myopia progression being greater
than that determined for axial elongation (as outlined in the
accompanying IMI – Interventions for Controlling Myopia Onset
and Progression Report).18 Indeed, high-dose atropine not only
limits the progression of myopia but also may even slightly
reduce the refractive error in the first year.111 This might reflect
a suppression of the tonus of accommodation under the chronic
effect of cycloplegia. This finding is relevant as it might justify
the very high efficacy of this treatment in the first year or so and
also help to explain the large rebound effect, part of which
might be no more than the recovery of normal accommodation
function. Thus, claims made for MC efficacy should not be
limited to refractive error or axial length measurements in
isolation but rather on both and the correlation between them
reported. Rebound effects should also be reported and
considered where such information is available.
3.2.3 Avoiding Non-Evidence-Based Claims/Recom-
mendations. A number of animal studies carried out in
different species have shown that peripheral refraction is
important in the emmetropization process, such that relative
peripheral hyperopic and myopic defocus can induce and
inhibit myopia progression, respectively.159–167 Further details
are provided in the accompanying IMI – Report on Experi-
mental Models of Emmetropization and Myopia.168 The latter
has led to the assumption that inducing relative peripheral
myopia through optical device use would reduce myopia
progression in humans. Such an assumption has been applied
in the development and marketing of devices for MC without,
in many cases, confirmation that such devices are effective for
MC in humans. It should be noted that myopic defocus
induced in human subjects with optical devices105,169,170 can
differ inherently from that produced by optically imposed
defocus in animals, where exposure to defocus is generally
substantial in terms of both magnitude and duration.159–167
Furthermore, large studies in humans have indicated that the
effect of peripheral refraction appears to be design specific and
may not, in all cases, impact myopia progression.171,172 It is
also common to find professional articles and presentations at
conferences providing recommendations about customizing
certain contact lens types to enhance MC efficacy, the
evidence for which may be anecdotal rather than evidence-
based.173 Whereas some of the anecdotal information can be
useful for the practicing ECPs, special care should be taken in
adopting recommendations lacking robust scientific evidence.
There is evidence in the literature for certain devices having
a role as being effective12,13,17,96,129 and relatively safe92–95 in
reducing myopia progression. Ultimately, MC efficacy should
be demonstrated in controlled clinical studies on human
participants and confirmed by regulatory bodies to obtain
marketing authorization or by independent research laborato-
ries in case of off-label/unlicensed treatments, rather than
basing claims of MC on extrapolation of results from animal
studies or presumption of equivalence. Until products obtain a
marketing authorization for MC in children, manufacturers
should consider compiling a list of selected, evidence-based,
off-label/unlicensed MC use of their optical devices to share
with those ECPs requesting such information, such that
practitioners can make informed decisions regarding the use
of such products.
3.3 Academics
Academics have an important role in disseminating scientific
information related to the safety and efficacy of approved and
nonapproved uses of MC treatments, which is typically
undertaken in the form of peer-reviewed journal articles, in
addition to abstracts and presentations at major scientific
conferences. As myopia increasingly becomes a topic of
discussion at the level of public health policymakers, it is
timely for academicians to be cognizant of their duty to inform
and continuously seek up-to-date resources in the field, so that
accumulated knowledge on the topic becomes available in the
public domain for advancing this important public health
issue.142
3.3.1 Examples of Public Health Initiatives. In the late
1990s, the National Committee on Myopia was developed in
Singapore in response to the alarming increase in myopia
prevalence that was being observed compared to the previous
decade.174 The threat of complications associated with the
development of high myopia warranted disease prevention
measures. The National Myopia Prevention Programme that
ensued was an attempt by the Singaporean Health Promotion
Board to decrease the prevalence of myopia in school
children.174 Despite myopia prevalence rates that remain
among the highest worldwide, this program has proven to be
a successful one. It continues to influence public health
policies and, equally as important, has created invaluable
public awareness on myopia at national levels, focusing on
schools and educational institutions, which, in turn, have led to
a much more informed patient population that recognizes the
risks of high myopia and is more amenable to potential MC
interventions.
In March 2015, a global scientific meeting on myopia was
jointly held by the World Health Organization and the Brien
Holden Vision Institute at the University of New South Wales in
Sydney, Australia.175 This meeting was held in light of concerns
about the current and future impact of myopia within health
care systems around the world. Important definitions were
clarified, distinguishing ‘‘myopia’’ from ‘‘high-myopia’’ and
agreeing upon characteristics of the clinical diagnosis of
MMD.175 Additional recommendations ranged from the use of
cycloplegic drugs in myopia screenings to areas where further
investigation would be beneficial to improve evidence-based
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management of myopia, such as the need to have sound
worldwide epidemiologic data.
In September 2016, the FDA held a public workshop titled
‘‘Controlling The Progression Of Myopia: Contact Lenses And
Future Medical Devices.’’176 This meeting brought together
prominent members of multiple interest groups who acknowl-
edged the increasing prevalence of myopia and the need to act.
The overall goal of this workshop was to reach a consensus for
clinical trial design attributes for obtaining FDA marketing
authorization of potential devices to control the progression of
myopia. This event was the first of its kind to bring together
interdisciplinary bodies that all see value in adopting MC
practices and, to date, has seen the publication of two papers
describing the meeting.177,178
These are just a few examples of how the global increase in
myopia prevalence and rates of myopia progression in the
youngest patient population has caught the attention of global
health agencies. The response of these agencies to supply
public information, much of which resides on the internet and
is not evidence-based, puts the onus on academics to ensure
that accurate information is provided to both clinicians and the
public.179
3.3.2 Gathering and Building Sources of Information.
To inform others, there must be a reputable knowledge base.
The growth in the scientific literature on the subject matter of
myopia has accelerated in the last century. In 1957, when
Robert Morrison reported on a case series of patients who had
been steadily increasing in their myopia, he was cognizant of
the potential pathologic consequences these individuals could
face in their future.180 A cohort of these myopic patients were
fitted with rigid contact lenses flatter than their flattest
keratometric measurement for daytime wear and they were
followed for up to 2 years, in an attempt to prevent their
myopia progressing. Fast forward 60 years and although we
may appear to understand the dynamics of how a rigid lens can
be designed to modify the physiologic growth of the eye, the
field of MC is continuously evolving. Academics play an
important role in ensuring that this evidence base continues to
grow.
3.3.3 Bridging the Gap Between Academic Research
and Clinical Practice. Many academic institutions and
professional organizations, in their commitment to providing
lifelong learning, offer continuing education programs, cours-
es, and workshop options. ECPs using these resources seek
high-quality, evidence-based education to implement into their
own clinical practices. Other potential sources of educating
ECPs include professional (non-peer-reviewed) publications,
presentations at national and international meetings, and direct
peer-to-peer interactions.
3.3.4 Education Beyond the Field of Eye Care. In the
prevention of myopia progression, it is not solely professionals
in the eye-related fields who should be well versed on the
subject matter. School-based interventions are already in use in
Taiwan and China, including mandatory outdoor time and
reduced homework hours.181 Elementary school teachers need
to be made aware of these new methods and be able to inform
parents and students and provide access to appropriate
resources. Pediatricians and other HCPs should also be well-
informed and involved in MC programs. Resources should be
regionally applicable and developed with input from scholars,
with reference to the scientific literature that is currently in
circulation.182
3.4. Eye Care Practitioners
3.4.1 Ethical considerations for ECPs. It is well-
documented that increasing levels of myopia leads to a higher
risk of potentially blinding ocular pathologies, such as
glaucoma, MMD, and retinal detachments.2,6,8,22,183 Therefore,
not treating progressing myopia with some form of MC
treatment is likely to expose patients to a higher risk of ocular
complications in the future. However, it should be pointed out
that although the reduction in myopia and axial length
elongation of the eye has been proven with some MC
therapies, there have yet to be long-term studies that
demonstrate that MC treatment does lead to a significant
reduction in the incidence of these potentially blinding ocular
pathologies later in life. Thus, ECPs are faced with a dilemma.
They do not want to leave the patient without treatment, as
this can be interpreted as an omission of professional duties.
However, they do not want to administer an insufficiently
proven treatment and assume all the risks, which the
regulatory approval process (as well as medical malpractice
law) would normally avoid, for the patients’ protection.133
Some physicians have indeed been involved in legal claims
related to adverse reactions occurring from the prescription of
medications for off-label use.75,184,185
To avoid potential prosecution for malpractice in the
prescription of MC treatments, the ECP has to justify the
professional rationale behind the prescription of such treat-
ments. When prescribing an off-label/unlicensed MC treatment,
an increased level of caution and monitoring must be
demonstrated to monitor for any adverse events. The ECP
should consider prescribing an off-label/unlicensed treatment
option for MC if there is sufficient evidence supporting its safety
and efficacy. When such proof exists, failure to prescribe an off-
label/unlicensed MC treatment could, arguably, result in an ECP
being liable for not following the appropriate standard of care
for their patient. The patient should be adequately informed
about the off label/unlicensed nature and the possible existence
of unknown risks for any prescribed treatment, although an ECP
may not necessarily be subject to professional liability for
nondisclosure of the off-label nature of the treatment.186
Parents/guardians should be in a position to make a well-
informed decision regarding whether a child should be treated
with a conventional tested and approved treatment, if available,
or with an off-label/unlicensed treatment, which might give the
chance of a better result, but at the same time, may have
unknown risks. Furthermore, the ECP is obliged to notify the
patient when the health insurance provider could refuse
reimbursement of costs, as well as the level of costs due to
the off-label/unlicensed status of the treatment.
In some countries, off-label/unlicensed use of medicines is
not reimbursed unless they are mentioned in HCP guidelines.
Some physicians believe that providing patients with informa-
tion about off-label use may afford greater protection from
future liability suits.186 However, no court in the United States
has mandated that a physician must disclose the off-label use of
a drug throughout the informed consent process.58 Arguments
against disclosure include that such process may ‘‘excessively
frighten’’ patients and that constantly reviewing and providing
extensive risk/benefit information may distract attention away
from other more important patient care issues.58 Nevertheless,
from an ethical perspective, patients should be clearly
informed about a drug or device’s status of authorization, such
that they are in a position to make informed decisions
regarding treatment alternatives. It has been shown that
patient’s knowledge regarding a drug’s status of authorization
is frequently lacking and, when adequate information is
provided, patients often refuse off-label treatments.187
To help determine whether the standards of practice are
being met when prescribing off-label treatments, authors have
proposed that the HCP carefully consider five points:75,186,188
1. Does the native drug or device have local regulatory
approval?
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2. Has the off-label use been subjected to substantial peer
review?
3. Is the off-label use medically necessary for treatment?
4. Is the use of the medication nonexperimental?
5. Has the patient been informed and agreed to off-label
treatment?
To minimize liability risks, off-label drugs or devices should
be prescribed in ‘‘good faith, in the best interest of the patient,
and without fraudulent intent’’.188 Following this approach
will ensure the FDA’s requirements are met, in that the HCP
prescribing medications for off-label use should ‘‘be well
informed about the product, to base its use on firm scientific
rationale and on sound medical evidence, and to maintain
records of the product’s use and effects’’.189
A flowchart to aid with decision-making regarding the
prescribing of off-label versus on-label options is described in
the Figure.
3.4.2 Information Provided to Patients and Parents. In
addition to information regarding off-label/unlicensed use of
products, other information of clinical relevance should be
provided. For instance, refractive surgeons offering corneal
refractive surgical options (e.g., LASIK) to improve unaided
vision should ensure that patients understand that such
treatments do not, in any way, mitigate the risks of developing
axial length-related myopic complications in later life. Like-
wise, patients informed about the benefit of overnight OK lens
wear in temporarily correcting refractive error to enable good
unaided visual acuity in the daytime, may confuse this aspect of
visual correction with claims of reduced myopia progression
and axial elongation, and this issue needs clarification.
3.4.3 Guidelines for Treatment. As discussed previously,
having access to guidelines on MC treatment developed by
professional bodies would be ethically and legally desirable.
However, following such guidelines will not exempt ECPs from
professional responsibilities and liability in the prescription of
off-label/unlicensed MC treatments. When considering pre-
scribing a treatment for MC, the ECP should ideally begin by
considering any on-label products that may be available and
contemplate off-label/unlicensed prescribing only if no on-
label options are available or if these options would be
inappropriate for the patient. It has been reported to be
common practice by HCPs in Europe to switch to off-label
medicines when there is a lack of effectiveness with on-label
products.85 In case of treatment alternatives where one
product is off-label/unlicensed and the other is licensed, but
from the HCP’s point of view both alternatives are equivalent,
the patient’s contribution in the decision-making process is
critical.58,133
3.5 Patients
The need for patient compliance is of key importance with any
treatment, but it is of particular relevance for off-label/
unlicensed treatments. In the latter case, higher levels of
monitoring than normal are required to warrant both safety
and efficacy with the treatment. Therefore, the patient needs
to fully agree to any extra measures of precaution indicated by
the ECP.
A further aspect of compliance relates to patient compli-
ance with the MC treatment prescribed, as only occasional use
of the prescribed MC contact lenses or spectacles, or failure to
use atropine as prescribed, will inevitably impact the treatment
efficacy. Indeed, longer wearing times exerted a greater MC
effect with a soft contact lens, confirming that wearing
compliance does indeed impact treatment efficacy.156 Finally,
compliance with issues such as contact lens storage, replace-
ment, and case hygiene can all impact safety of the prescribed
device and patients must understand their role in this to ensure
maximal chances of contact lens success.190–195
3.6 Impact on MC Therapies
The increasing prevalence of myopia is driving off-label and
unlicensed use of treatments options for MC in the absence of
on-label therapies. Several incentives at governmental, regula-
tory, health care, and professional level have been implement-
ed in the past and some others have been suggested, but they
FIGURE. Flowchart describing the options for on-label versus off-label prescribing options for MC from a regulatory standpoint. Adapted from
Wittich et al.75
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have had little impact on the number of products approved for
pediatric indications. Regulatory bodies do not normally
regulate the way medicinal products are ultimately used in
practice. The prescription of a product, regardless of whether
on-label, off-label, or unlicensed, is a decision taken within the
relationship between a patient and the treating HCP.
Companies are not typically permitted to promote
treatments for MC that are not approved for that purpose,
although the dissemination of scientific information that is
truthful and not misleading about unapproved uses is
allowed. Academics have an important role in disseminating
scientific information related to the safety and efficacy of
potential MC treatments. The latter is likely to help ECPs
make balanced informed clinical decisions about unapproved
use of drugs and devices that might help advancing public
health, particularly until approved clinical guidelines for MC
treatment became available. Nevertheless, the treating ECP
can be trapped in the difficult dilemma of whether or not to
treat progressing myopia in children. ECPs involved in
prescribing MC treatments should show an increased level
of caution and monitoring with off-label or unlicensed
therapies. The option to prescribe off-label/unlicensed MC
treatment options based on the most credible available
evidence, rather than restricting prescriptions to indications
only approved by regulatory bodies, is likely to work in the
best interest of the patient.
Patients should be well-informed about the nature of the
product’s marketing authorization status for the intended use
and in case of off-label/unlicensed treatments that the risks
associated with the treatment might be unknown and that
there might be possible difficulties in connection with the
reimbursement of the treatment costs by health insurance
companies. Such information should be provided in a neutral,
balanced, and nonbiased way and be accompanied by easily
accessible online and printed information. The use of informed
consent and assent forms are strongly recommended. Addi-
tionally, until more on-label options become available, ECPs
should continually educate themselves about off-label/unli-
censed uses of MC treatments to weigh the risks and benefits
and provide the best possible care for their patients.
4. REGULATORY CONSIDERATIONS
Regulation of drugs and devices helps to protect the health and
safety of communities, improves patient access to high quality
products, increases confidence in the health system, and
creates stable conditions for manufacturers to pursue novel
therapies. However, drug and device regulations vary signifi-
cantly from country to country (see Table 3 for some examples
of regulatory agencies). Furthermore, in most countries, drugs
and devices will be regulated by different governmental offices.
As countries advance economically and socially, there is
considerable flux in regulations, with a strong tendency to
greater formality. MC treatment is a relatively recent concept
and, therefore, regulatory guidelines on this topic are yet to be
clearly established. Similarly, legal authorization for practition-
ers and commercial bodies to deliver and advertise treatments
to the public or practitioners vary substantially between
countries. Addressing all of these regulatory topics compre-
hensively by country is beyond the scope of this document.
Therefore, the following discussion presents a general over-
view, highlighting some of the relevant principles appropriate
for regulation of MC treatments. Because of its prominence,
influence, and well-established procedures, the US FDA is
referenced to provide examples of regulatory processes. The
two main areas addressed are (1) clearance for use of a product
from governmental authorities and (2) licensing of practition-
ers to implement MC treatments.
4.1 Product Registration
4.1.1 Classification and Approval. Approval of a drug by
a regulatory body naturally relies on the risk-benefit assessment
and is informed by science, medicine, policy, and judgment, in
accordance with applicable legal and regulatory standards.
Different regulatory pathways may be used to enhance
efficiency and shorten timelines for the development and
approval of novel drugs or to expand indications for existing
drugs. For example, the Center for Drug Evaluation and
Research of the US FDA has applied different designations for
novel drugs, such as first-in-class, orphan, fast track, break-
through, priority, and accelerated approval, often with drugs
falling into multiple designations. It does not appear that there
are novel drugs on the immediate horizon for MC, although
this may change in the future.196
Drugs under consideration for MC would most likely fall
under the banner of new uses for previously approved drugs
(termed ‘‘efficacy supplement’’ by the US FDA), with new
indications and labeling required to address the new indica-
tion. The approval of such drugs for new use may be
facilitated, in part, by existing data, but often will need to
undergo stringent efficacy and safety testing similar to new
drugs. Pathways for development and approval are best
explored using documents such as International Organization
for Standardization standards, guidance documents, and
manual of policies and procedures, in addition to discussion
of specific requirements with regional authorities. Some
indication of the requirements for obtaining approval for a
MC drug may be obtained from the transcripts of the
Dermatologic and Ophthalmic Drugs Advisory Committee
meeting of the FDA from 2003197 and in a recent paper by
Novack.196
Further requirements for some jurisdictions may also be
obtained by considering the experimental designs of phase 3
studies for MC drugs, as may be found in clinical trial registries.
Some countries may rely on approvals obtained in lead regions
(e.g., United States or Europe) to assist in regulatory decision-
making. Considerations for experimental designs in submis-
sions for approval of drugs may be found in the accompanying
IMI – Clinical Myopia Control Trials and Instrumentation
Report.144
Devices are commonly classified according to risk for the
purposes of providing guidance as to the type of testing that
will be required. Different jurisdictions take different ap-
proaches but, by way of example, the US FDA divides devices
TABLE 3. Examples of Regulatory Bodies
Market Regulatory Body
Australia Therapeutic Goods Administration
Canada Health Canada
China Chinese FDA
Europe European Medicines Agency
Hong Kong Medical Device Control Office and Drug Office
Japan Pharmaceuticals and Medical Devices Agency
(PMDA, or Koseisho)
Singapore Health and Science Authority
South Korea Ministry of Food and Drug Safety
Taiwan Taiwan FDA
United Kingdom Medicines and Healthcare Products Regulatory
Agency (MHRA) of Department of Health
United States Food and Drug Administration
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into three classes. Class I devices are low-risk medical devices.
These will generally be exempt from the need for regulatory
approval (premarket notification) but are not exempt from
other general controls, such as the need to be manufactured
under a quality assurance program, be suitable for the intended
use, be adequately packaged and properly labeled, and have
appropriate registration with the FDA. Spectacle lenses (and
frames) for myopia correction currently fall into this category.
FDA Class 2 devices are more complex devices entailing a
higher risk profile than Class 1 devices. Such devices generally
require a 510(k) premarket notification to demonstrate that
they are at least as safe and effective as an existing product or
PMA where no predicate device exists. Submissions are
reviewed prior to marketing clearance. Class 2 (and 3)
products are also subject to design controls, a set of quality
practices and procedures that control the design process to
ensure that a product meets user needs, intended use, and
specified requirements. Daily wear soft contact lenses for
myopia correction are currently classified as Class 2 devices.
FDA Class 3 devices are the most complex devices and carry
the highest risk profile. Soft and OK contact lenses for
refractive correction and overnight use are classified as Class
3 devices. These products require a PMA, the most stringent
regulatory device category. PMA approval is based on a
determination by FDA that the PMA contains sufficient valid
scientific evidence to assure that the device is safe and effective
for its intended use.
To our knowledge, there are only two products (both
multizone soft contact lenses) that currently have general
regulatory clearance anywhere in the world (low-dose atropine
has limited regulatory status in Singapore and Malaysia). Both
contact lenses are Conformite´ Europe´enne (CE)-marked, which
is the manufacturer’s self-certification that the products
conform to the health, safety, and environmental protection
standards within Europe. Because the dossiers for CE marking
are not public, there is no information available about the
standards or evidence used by the manufacturers for self-
certification with respect to safety and efficacy.
Because no MC devices have FDA clearance, regulatory
requirements remain unclear. The FDA held a public work-
shop, cosponsored with other professional bodies, with the
purpose of discussing ‘‘clinical trial design attributes for studies
using contact lenses or other medical devices to control the
progression of myopia’’.176 Two papers have been published in
relation to this meeting, one reviewing previous key studies
and a second discussing study design and regulatory issues
relevant to future clinical trials.177,178 Further discussion of
experimental design considerations is presented in the
accompanying IMI – Clinical Myopia Control Trials and
Instrumentation Report.144
For both drugs and devices, regulatory bodies may impose
post-approval requirements, such as postmarket surveillance.
Again, information about what might be required in this regard
is speculative at this time.
4.1.2 Practitioner Licensing. The matter of practitioner
licensing to prescribe MC devices or drugs is complex due to
the fact that the scope of practice and levels of training of ECPs
vary markedly from country to country. In many developed
countries (e.g., United Kingdom, United States, Australia, and
Canada), the profession of optometry has matured to that of an
independent primary eye care level (Category 4 in the ‘‘Global
Competency-based Model of Scope of Practice in Optometry’’
of the World Council of Optometry).198 In these countries,
optometrists are qualified to prescribe most of the typically
available MC treatments (in some, to prescribe drugs such as
atropine, a higher qualification is required). However, in many
countries, optometrists may only be allowed to prescribe
spectacles lenses or contact lenses but not drugs. In certain
countries, contact lenses can only be prescribed for minors by
ophthalmologists and not optometrists. Furthermore, in some
countries, there is no specific legislation on the practice of
optometry and there is no regulatory control of the prescribing
of optical devices, including contact lenses.
This makes the regulations around the prescribing of optical
devices for MC somewhat complicated. For example, once a
soft contact lens or OK product receives FDA approval or a
European CE mark, ECPs in these markets may prescribe these
products without any limitation. However, in China, once
these same products are approved by the Chinese FDA, soft
lenses can be fitted by practitioners in local hospitals, eye
clinics or optical retail premises, but only practitioners with a
medical license or those working in a hospital, eye clinic, or
optometry practice that has received a practicing medical
license can prescribe OK devices. Optical retail premises in
China without a practicing medical license would not be able
to prescribe OK lenses, although they can prescribe soft
contact lenses.
It is, thus, a complex matter to review and/or standardize an
‘‘indication of treatment,’’ when both product registration and
practitioner legislation in different countries/territories are
taken into consideration.
4.2 Relevant Regulatory Requirements
It is clear that the complexity of regulatory frameworks pose a
challenge in standardizing the indications for the use of MC
treatments in different countries or regions. This, however,
does not prevent the global industry from adopting a standard
protocol and good practice guidance to meet ‘‘general’’
regulatory requirements, including even the most stringent
ones such as FDA in the United States and Pharmaceuticals and
Medical Devices Agency in Japan.
4.2.1 Good Laboratory Practice and Good Manufac-
turing Practice. In the optical, pharmaceutic, and ophthalmic
industries, Good Laboratory Practice and Good Manufacturing
Practice require clear protocols to be established before a
prototype or a finished product is produced.
A number of global standards, such as British Standard,
European Standard, or International Organization for Standard-
ization, are available and used globally in the development and
licensing of ophthalmic medical devices. For example, British
Standard, European Standard, International Organization for
Standardization 11981:2009 on ‘‘Ophthalmic optics, contact
lenses and contact lens care products. Determination of
physical compatibility of contact lens care products with
contact lenses’’ is a relevant standard for many MC devices.
4.2.2 Good Clinical Practice (GCP). GCP involves
standards and guidelines required for designing, planning,
conducting, monitoring, documenting, analyzing, and report-
ing of clinical trials. This ensures that the conduct of clinical
trials follow internationally acceptable ethical and scientific
standards. Optical, pharmaceutic, or ophthalmic industry
involved in MC should adopt GCP for their clinical trials and
is a requirement from most IRBs. This will facilitate the
recognition of the clinical results by regulatory authorities,
with potential to establish a recognized norm in MC studies.
4.3 Industry Accreditation of Prescribers
A point worthy of consideration relates to the potential
accreditation or training of ECPs in the prescribing of devices
or pharmaceutic agents for MC. In unregulated markets, this is
difficult to achieve, but in those in which a company has control
over whom has provided the MC product then it would be
worthwhile for companies to consider what is required to
access and prescribe the product. Industry should effectively
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communicate and participate in advocating the importance of
early intervention in MC and in providing high-quality training
and education for practitioners to support their implementation.
One such example relates to the recent commercial release
of a soft multizone contact lens that has received regulatory
approval for MC in several countries. To have access to a fitting
set of lenses and be permitted to order the lens, prescribing
practitioners were required to undergo a 1 hour web-based
educational program that discussed the growing problem of
myopia, the pathologic implications of high myopia, expected
clinical results, and how to fit and problem-solve issues with
the device in pediatric patients.
4.3.1 Educational Materials. There is an urgent need to
create standardized educational materials on myopia risk and
MC treatments. Such educational materials should cover areas
such as epidemiology, the public health burden due to myopia,
contemporary research in MC, interventional options, and best
clinical practices for MC. Currently, there are many different
groups of researchers, clinicians, and scientists across the
globe expending efforts to provide information on MC
treatments, and these efforts often overlap across groups.
For practitioners to appropriately prescribe MC treatments
in their clinical practice, it is important that materials used for
educational purposes meet the following criteria as a minimum
standard:
 Present evidence-based information on the efficacy,
safety, and benefit/risk ratios for each treatment when
applied to different population groups (e.g., different
ages, races, and educational levels);
 Present this information in a clinically oriented manner
that the practitioner may relate to.
Independent stakeholders such as the IMI could play a key
role in the development of such educational materials, which
would need to be developed for ECPs and other related
professionals (pediatricians, general practitioners, and school
teachers) with widely varying educational backgrounds. These
materials would be beneficial for all stakeholders, including
industry and regulatory bodies, as well as providing a global
approach for MC by practitioners across the world.
4.3.2 Ongoing Educational Requirements. To acquire
and maintain standardized minimum clinical competencies,
knowledge, and skills in providing MC treatment and
management, continuous training is essential. It is recom-
mended that MC treatment and management training incorpo-
rates current best practice principles used in continuing
professional development (CPD) courses. CPD is a mandatory
requirement in many countries where optometry and ophthal-
mology are mature professions (e.g., Canada, United Kingdom,
United States, Australia, and Singapore) but is voluntary for
optometry in others (e.g., Hong Kong). Therefore, standardiz-
ing MC education based on CPD requirements is a complex,
yet important, principle to apply where possible.
Initially, it is recommended that stakeholders consider
establishing a standardized global CPD credit system that is
aligned with the different tiers of education or training
worldwide. To achieve these standardized programs, open
communication and close collaboration with local professional
and regulatory bodies worldwide is important. Once ‘‘accred-
ited’’ following such a period of training, regulatory bodies
(both government and professional) and/or industry could
develop and make available a database of ‘‘approved’’ prescrib-
ers of the device or pharmaceutic agent intended to provide MC.
This would ensure that patients would understand that the
prescribing ECP has obtained the appropriate training to use the
device or pharmaceutic agent in an appropriate manner.
In countries where graduating optometric competencies
include MC management and there is already a well-developed
CPD program, an official extra CPD system is probably not
needed. In these places, ECPs might prefer to be involved in a
fellowship process involving the myopia specialty or member-
ship of a Myopia Association as proof of interest in staying
current with changes in the myopia field.
5. RESPONSIBILITIES IN THE DISSEMINATION OF
INFORMATION
The volume of information available regarding MC efficacy is
increasing rapidly, and assessing the quality of publications
claiming potential benefits from these treatments may prove
difficult for both patients and practitioners. One major issue
relates to the fact that MC treatments do not impart an
immediate effect but rather an expected outcome that is
several years in the future. Potential outcomes should be
explained in a non-biased way and realistic expectations
provided.
Potential sources of bias in information presented to the
public include:
 Claims on efficacy of the treatments from limited-term
clinical trials;
 Claims on efficacy of treatment based from animal
studies;
 Claims on efficacy of treatment based solely on presump-
tion of device equivalence;
 Claims on mechanisms of action of treatments;
 Claims on cumulative efficacy in the long-term;
 Claims on long-term reduction of comorbidities related to
myopia progression.
To filter out potential ‘‘exaggerations’’ of the impact of MC
treatments, the information presented must rely on robust
scientific evidence. Such information is typically available in
scientific journals, and it is important that clinicians have
access to the sources supporting the claims made and evaluate
the publications appropriately. Additionally, scientific publica-
tions are not easily assimilated by patients (children) undergo-
ing MC treatment or their parents/guardians, and thus, efforts
should be considered to present such information in formats
that they can more easily comprehend. Finally, as MC
treatments become more popular and their use expands, it is
necessary to update the information on the post-market
experience such that clinicians and patients are made aware
of the longer term efficacy and safety of such treatments.
This section will address these topics from the standpoint of
the stakeholders participating in marketing medical devices
and treatments for MC to both clinicians and their patients.
5.1 Peer-Reviewed Scientific Journals Versus
Clinical Journals
Evidence-based clinical practice is supported by the body of
literature published on the topic of interest. The evidence used
should use the highest standards of research design, method-
ology, and conduct. In a general sense, the highest standards
for evidence supporting new devices or treatments are derived
from the conduct of randomized, controlled, masked clinical
trials published in peer-reviewed scientific journals.
Although the open access regime of publication is
becoming more common, most scientific journals are still
available through scientific or professional organizations and
subject to subscription-based access. Clinicians not involved in
research activities may be more familiar with clinical journals
that are not always peer-reviewed and, therefore, are poten-
tially subject to bias. There are multiple examples of misuse of
scientific evidence in clinical recommendations published in
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both peer-reviewed and non-peer-reviewed journals. Dissemi-
nation of information with suboptimal levels of scientific
evidence is an increasingly relevant issue199 and given the
importance of this issue to the clinical decision to undertake
MC treatment in a vulnerable population, it is vitally important
that the utmost care is taken in the reporting of MC studies and
their outcomes and conclusions.
5.2 Public Dissemination of Information for
Patients and Their Families
Patients rarely have access to or consult scientific literature.
Even if access is available, the increasing trend of using
technical information makes the scientific literature incompre-
hensible to most people. Therefore, scientists, practitioners,
industry, and organizations with expertise in MC should direct
efforts to provide the public with trustworthy and transparent
information in an effective manner so that parents can
understand the available treatments and their potential short-
term and long-term benefits as well as risks. To be truly
effective, the challenge is to provide the information in a way
that is understood by the lay person, allowing them to judge
the efficacy and safety of the treatments for themselves.
5.3 Confidentiality Versus Transparency
There is increasing pressure on researchers and industry to
provide a detailed database of their research results. Some
peer-review journals and funding agencies are driving this
change to expand the concept of Open Access not only to the
contents published but also to the source data to increase
transparency. This could create potential conflicts with the
confidentiality of the participant’s data, which must be
protected by adequate anonymization of any databases.
Another serious risk for transparency in dissemination of
information from clinical trials is publication bias, which tends
to lead to the more frequent publication of positive results
rather than negative results.200,201 The need to publish negative
and positive results is very important to build up an unbiased
body of evidence around the efficacy and safety of medical
devices and treatments. In the MC context, negative results
might not be disclosed due to an effect contrary to the one
expected or because the clinical benefit found is not enough to
make the device or treatment appealing for stakeholders. Of
note is that there are several publications of nonclinically
significant results in the MC arena and several other studies that
have published negative results.98,104,109,202–204 This increases
confidence that publication bias in this domain as of now might
not be a problem, but this issue must be considered, as the
number of publications in this field continues to rise.
5.4 Handling and Reporting of Discontinuations in
Clinical Trials
Clinical trials on MC involve several years of follow-up and, thus,
participant drop-out is common, varying from less than 10% to
over 25%. There are several reasons that justify early discontin-
uation from a clinical study. Some of them (e.g., loss of interest
due to nonobservable effect of the treatment) might have an
impact on the overall efficacy, whereas others (e.g. complica-
tions) might have an impact on the final safety outcomes. High
levels of early withdrawal, particularly when this is asymmetric
in different treatment groups, might also negatively impact the
comparability of the results between treatment arms. The
statistical power may also be at risk when modest samples are
initially recruited and/or high rates of withdrawal are observed,
which may limit the ability to estimate the treatment effect. To
understand the impact of this factor, the discontinuation rate in
each group and subgroup should be reported, as well as the
reasons and the impact on the randomization process and final
statistical power.
5.5 Subgroup Results from Clinical Trials
Our understanding of the potential factors impacting myopia
progression has increased over the past decade and so has the
number of factors that can potentially influence the efficacy of
MC devices and treatments.104,205 Authors reporting on clinical
trials frequently discuss their findings in light of this
knowledge to find a mechanistic explanation for their results.
Unfortunately, study design and results analysis do not always
allow testing of the hypothesis to confirm the cause and effect
relationship between the results and the proposed mechanism.
Therefore, future clinical trial design should anticipate the
inclusion of subgroups (e.g. phoria status, relative peripheral
refraction, and accommodative lag) that might help to test the
hypothesis of working principles involved in the design of the
treatment device. This will undoubtedly have an impact on the
complexity and costs involved in the clinical trial recruitment.
When different subgroups are included in the analysis, their
results should be communicated separately to help practitioners
decide the clinical scenarios where a given device or treatment
might be more effective. Similarly, when different treatment or
control groups are included in the same trial, reporting should
specify the results on all groups. Providing such data will allow
the stakeholders to evaluate the absolute efficacy of the
treatment and not only the percentage efficacy compared to
the control group. When more than one treatment group is
involved, the outcomes of all groups should be reported and not
only the results of the treatment of interest.
5.6 Sample Sizes
Sample size calculations must be conducted a priori to warrant
sufficient statistical power to test the hypothesis being
investigated, (e.g., difference between treatment groups in
axial elongation and/or myopia progression over a certain
period of time). This estimation may be challenged by the early
drop-out of participants during the study, which may have an
impact on the statistical power of the final outcomes. The
publication of research results should include details on the
statistical power for the sample size that was initially intended
and the power for the sample that finished the study. This will
provide the stakeholders with a sense of the risk of erroneously
accepting the null hypothesis (Type II error). Similarly, the
report should include the statistical significance used in the
statistical analysis to provide a sense of the risk to erroneous
rejection of the null hypothesis (Type I error).
5.7 Consideration of Location of Studies
Previous studies have shown that a given treatment (e.g., OK)
might not present the same efficacy in clinical trials conducted
in different countries and ethnic groups.147,148,151,152,157
However, this information was collected from a variety of
studies that did not permit the exclusion of other factors apart
from ethnicity and geographic location. In clinical trials where
different ethnicities were involved, no significant differences
were reported regarding the ethnicity of the participants
enrolled,98,206 although accounting for this factor would
require larger populations than those studied. A recent
multicenter clinical trial conducted in Europe, Asia, and North
America showed that ethnicity was not a determinant factor in
the efficacy of a dual focus soft contact lens (Chamberlain P, et
al. IOVS 2017;94:ARVO E-Abstract 170075). Although further
information is produced on the potential differences in efficacy
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of treatments between ethnicities and/or geographic location
of the myopic patients, efficacy data should be accompanied
by information regarding the sites and ethnicity of the
participants enrolled, as this may differ between geographic
locations and ethnicities.
5.8 Rebound Effects
Rebound is a well-known effect in pharmacology and is
observed as a manifestation of the symptoms or signs when
medication is discontinued or reduced, once the medical
condition was appropriately treated. Rebound effect in the
context of MC represents a faster axial elongation and increase
in refractive error than that expected in a matched group,
upon cessation of the MC treatment. This has been shown to
various degrees with cessation of both atropine and OK.115,207
A potential rebound effect following the use of bifocal/
multifocal soft contact lenses for MC has not been studied
and warrants investigation.
Significant rebound in MC is particularly relevant, as this is a
treatment intended to reduce the long-term myopic changes that
occur in later life. If the potential benefit gained during treatment
is lost after treatment discontinuation, then this obviously
compromises the goal of the treatment. As the biological
mechanisms involved in MC with optic devices are still relatively
unknown, the same reasons that drive atropine rebound effect
might not apply to contact lenses or spectacles used for MC.
It is desirable to evaluate the rebound effect after MC
discontinuation to provide practitioners, parents, and patients
with realistic expectations on the long term benefits of MC
treatments and the ideal duration of the treatment to overcome
a potential faster progression after early discontinuation.207
Ideally, such studies should incorporate a control group, as it is
expected that the axial elongation will slow down naturally
with age. Communication of these outcomes should be
reported in comparison to a randomly assigned, age-matched
control population. It should also be noted that investigation of
potential rebound effects is subject to difficulties in study
design and ethical committee approval, as such testing would
naturally involve exposing participants to potential increased
rates of myopia progression.
5.9 Postmarketing Surveillance Studies
Contact lenses are medical devices, which are cleared for
marketing in relatively small clinical trials, based on showing
equivalence to currently marketed predicate devices. These
studies cannot usually assess the safety of these devices,
considering the relatively low incidence of adverse events with
such optical devices. However, once the products are
commercialized, sales increase and the likelihood of detecting
any complications increase.
Most of the treatments currently in use for MC involve
medical devices that have a degree of risk that ranges from low
to moderate.208 Given that these devices are being used on
vulnerable populations, it is suggested that postmarketing
surveillance studies postapproval should be undertaken, as
these may provide valuable data on such devices in the context
of misuse or safety.209–211
6. RESPONSIBILITIES IN MARKETING, SUPPORT AND
EDUCATION
6.1 Marketing and Guidelines
MC cannot be implemented widely without a strategy for
transferring the required knowledge and skills to ECPs, who
are in the front line of servicing the public, and to academics
who are key in nurturing the forthcoming generations of
clinicians.
Although there are many scientific conferences that include
information on MC through scientific papers or continuing
education lectures, these are typically annual or biannual
events that many practitioners will not have an opportunity to
attend. Many other scientific conferences involving medical
practitioners, pediatricians, and ophthalmologists may also
have MC sessions in the future. Structured and locally delivered
CPD in MC is critical to equip clinicians and academics with
the knowledge and skills required to best manage their
patients. Section 4.3.2 has already discussed the need for
CPD programs for HCP and the need to establish standardized
educational materials to cater for the varying levels of training
required in various countries or regions.
Key stakeholders in the development of this educational
material includes:
 ECPs
 Optic, ophthalmic, and pharmaceutic industries
 Regulatory bodies (for products)
 Legislative bodies (for practitioners)
 Health care agencies
 Academic institutions
 Vision and eye health institutions
 Professional bodies or associations
 Patient groups
In addition, it may be worthwhile to explore other channels
for partnership to secure financial support to market and
advocate for MC programs. This may include nongovernmental
organizations, nonoptic industries, or high net worth individ-
uals or firms. There is an increasing trend among commercial
companies to allocate revenue streams for corporate social
responsibility projects. Some are directed toward activities that
improve children’s lives (i.e., skill development, building of
schools, and learning capabilitie), whereas others are targeted
in health-related areas. The possibility of developing projects
that cross-fertilize these areas should be explored with regard
to MC programs.
Industry partners are likely a key source of funding, and any
MC programs will directly or indirectly benefit industry
through increased sales and/or the access to new markets.
Sponsorship for such programs needs to be managed ethically
and professionally to avoid any potential COI and to fulfill the
ultimate aim of benefitting patients.
7. CONCLUSIONS
Undertaking MC treatments on vulnerable populations creates an
ethical challenge for a wide variety of stakeholders. Regulatory
bodies, manufacturers, academics, and ECPs all share an ethical
responsibility to ensure that the products used for MC are safe
and efficacious and that the wearers understand the benefits and
risks of such products. For ECPs, it is essential to provide
appropriate information to patients who are at risk of developing
myopia or for whom myopia-related pathology could occur due
to rapidly progressing myopia. This IMI report highlights these
ethical challenges and provides stakeholders with a framework
to consider such issues in the development, financial support,
prescribing, and advertising of products for MC.
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YOUR BUSINESS INFORMATION HERE
What is myopia? Myopia (also called near-sightedness)
occurs when images focus in front of the retina, resulting in
blurred vision. Vision is made clearer by putting a spectacle
lens or a contact lens at the front of the eye to focus light onto
the retina so that the image is clear and in focus.
What causes myopia? We are not 100% sure why some
children become myopic and others do not. We do know that
there is most likely a genetic component, and if a child has
myopic parents, then they are more likely to become myopic.
There is also some evidence to suggest that excessive near
work could contribute to the onset of myopia. There is also
evidence to suggest that spending more time outside in
daylight could be a preventative measure to protect against the
onset of myopia
What can I do now that my child is myopic? It is
important that your child have clear distance vision, which is
most easily achieved initially with spectacles or contact lenses.
There are several options available that may slow down the
progression of myopia.
Why should myopia progression be slowed down?
Myopia control treatments have been shown to slow down
the progression rate of myopia by up to 60%. This would
mean that, although your child’s prescription may continue to
change, it would hopefully change more slowly than if they
were wearing a normal refractive correction, ultimately
resulting in a lower prescription. It is well-documented that
high prescriptions result in an increase in myopia-related
ocular complications, such as retinal detachment, glaucoma,
and myopic macular degeneration.
What options are available for controlling the
progression of myopia? There are various options available
that have been shown to slow down the rate at which myopia
increases:
 Progressive and bifocal spectacle lenses: your child
would wear their regular spectacle prescription in a
‘‘bifocal’’ design, with less power in the lower portion of
the spectacle lens. It is thought that by reducing the
demand on focusing for near work, myopia may not
progress as quickly.
 Enhanced Single Vision spectacle lenses: your child
would wear their regular spectacle prescription in a
‘‘multifocal’’ design. It is thought that by adjusting the
peripheral vision, myopia may not progress as quickly.
 Orthokeratology (Ortho-K): your child would wear
specially designed rigid contact lenses overnight and
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remove them in the morning. The lenses are designed to
alter the shape of the front of the eye so that your child
has clear vision without correction during the day. This
type of treatment has also been shown to slow down the
progression of myopia.
 Multifocal/Dual focus soft contact lenses: your child
would wear soft lenses during the day that are designed
to change the way that images focus on the peripheral
retina. These types of lenses have been shown to slow
down the progression of myopia.
 Atropine eye drops: low doses of atropine (0.01%) have
been shown to slow down the progression of myopia.
Your child would insert one drop of the atropine drug
into their eye once per day.
Are the treatment options safe?
 Spectacles: Typically wearing spectacles poses very little
risk to patients.
 Contact Lenses: Children are commonly fit with
contact lenses and are able to wear them successfully.
The (low) rate of complications related to contact lens
wear is similar in children and adults. There is a higher
risk of contact lens-related complications (including
corneal infection) in patients who wear contact lenses
overnight than those who wear contact lenses during
the day.
 Atropine: Low-dose atropine is considered to be safe for
children and has been shown to have a small effect on
pupil size and focusing ability compared to full strength
(1%) atropine.
Are these treatment options approved by (insert your
countries regulatory body, e.g., FDA, Health Canada,
etc.)? At the moment, there are only two products that have
regulatory approval as a product for myopia control. What this
means is that the other treatment options are being used ‘‘off-
label’’ or in a nonapproved manner. It should be noted that
there are many occasions when medications or treatment
modalities are prescribed in an ‘‘off-label’’ way by qualified
practitioners.
As examples:
 Orthokeratology is indicated for the management of a
myopic prescription and happens to have an added
benefit of slowing down progression.
 A regular soft multifocal contact lens has an indication for
vision correction for patients over 40 who are experienc-
ing reading difficulties, and fitting this approved lens to a
child would be using it in an ‘‘off-label’’ modality.
 Atropine 0.01% is not commercially available and has to
be specially formulated by a pharmacist. It does not have
an indication for myopia control and therefore would be
used in an ‘‘off-label’’ modality.
What complications or side-effects can my child
expect? Complications with any of the myopia control options
available are rare. Your child may notice the following:
 Orthokeratology—discomfort on lens insertion, difficulty
handling the lenses, or blurred vision during the day if the
corneal reshaping has not fully eliminated the prescrip-
tion.
 Multifocal contact lenses—difficulty handling lenses, or
ghosting of images under certain lighting conditions.
 Atropine—larger pupils leading to light sensitivity and a
slightly reduced ability to focus at near.
Complications other than these are very rare; however,
should your child experience any symptoms or signs related to
their myopia control treatment, you should contact the clinic
immediately.
There are four ways to potentially slow down the
progression of myopia in children. Each treatment has its
own risks and those have been explained to you. After
consideration of your child’s prescription and visual needs we
have decided that the best option to slow the progression of
your child’s myopia will be:
 Orthokeratology
 Soft multifocal contact lens
 Atropine
 Progressive and bifocal spectacle lenses
 Enhanced single vision spectacle lenses
Parents declaration: I understand the risks as explained
to me and indicated above. I also understand that some of the
treatment options maybe being used in an ‘‘off-label’’ modality.
I understand that there is no guarantee of the treatment
outcome for my child with the chosen modality.
Child’s name (print) _________________________________
Child’s name (sign) __________________________________
Parent’s name (print) ________________________________
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